ArticleDiscover oncology2026
DLX6-AS1 promotes the progression of Wilms tumor by sponging miR-195-5p to upregulate KIF23 in Wilms tumor cells.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWilms tumor (WT) is a frequently diagnosed cancer in pediatric patients. DLX6-AS1 contributes to the emergence of several cancers. Nonetheless, the role of DLX6-AS1 in WT remains unclear. This study aimed to explore potential mechanisms by which DLX6-AS1 promotes the progression of WT.
methodsDLX6-AS1, miR-195-5p, and kinesin family member 23 (KIF23) expression levels were measured by qRT-PCR in 22 pairs of tumor tissues and adjacent para-carcinoma tissues from WT patients, WT cell lines, and human renal tubular epithelial cell line (HK-2). The proliferation, migration and invasion, and epithelial-mesenchymal transition (EMT) like changes of WT cells were detected by CCK8, wound-healing, transwell assay and Western blotting.
resultsDLX6-AS1 was overexpressed 2-3 fold in WT tissues and cell lines compared to control tissues and cells. Silencing of DLX6-AS1 inhibited the proliferation of WT cells by 50%, and changed the expression of EMT related genes by 1.5 to 2 fold in WT cells. DLX6-AS1 acted as a sponge to upregulate the expression of KIF23 by recruiting miR-195-5p. The inhibition of miR-195-5p and overexpression of KIF23 partly reversed DLX6-AS1 silencing mediated suppression of migration, proliferation and EMT like changes of WT cells.
conclusionDLX6-AS1 could function as an oncogene to accelerate the development of WT by increasing the expression of oncogenic KIF23 by sponging miR-195-5p. DLX6-AS1/miR-195-5p/KIF23 axis is potential therapeutic target of WT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.